AstraZeneca announces the establishment of a cell therapy manufacturing facility in Shanghai

On March 19, AstraZeneca announced plans to establish a cell therapy commercialization production and supply base and an innovation center in the Shanghai Lingang New Area, for the commercial production and supply of autologous CAR-T cell therapy in China and other Asian markets. It will also become the first biopharmaceutical company in China with end-to-end cell therapy capabilities. On the same day, AstraZeneca signed a multi-party cooperation memorandum of understanding with the Shanghai Municipal Science and Technology Commission and leading UK research and financial institutions. (First Financial)